Physician profile
Niranjana Chellappa
NPI 1902399462
$652.85
in general payments reported to CMS, 2019-2025
15 companies · $569 in 2025
The $569 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $18.63 · 2024: $65.53 · 2025: $569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $617 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $616.84 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $180.66 | 2025 | Ohtuvayre |
| Glaxosmithkline, LLC. | $71.88 | 2025 | Nucala |
| United Therapeutics Corporation | $61.02 | 2025 | Tyvaso |
| Olympus Corporation of The Americas | $60.00 | 2025 | |
| Insmed, INC. | $56.44 | 2025 | Brinsupri, Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $31.17 | 2025 | Glassia |
| Genzyme Corporation | $30.95 | 2025 | |
| Mallinckrodt Hospital Products INC. | $24.54 | 2024 | Acthar |
| Regeneron Healthcare Solutions, INC. | $23.54 | 2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $21.16 | 2025 | Fasenra |
| La Jolla Pharmaceutical Company | $21.00 | 2024 | Giapreza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.99 | 2024 | Ofev |
| Edwards Lifesciences Corporation | $18.63 | 2022 | |
| Viatris Specialty LLC | $18.29 | 2025 | Yupelri |
| Grifols USA, LLC | $13.58 | 2025 | Prolastin-C Liquid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niranjana Chellappa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.